A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396 on ClinicalTrials.gov · last registry update 2026-07-07
An unusually large phase 3: 1,840 participants, more than double the 424 typical for the stage. The sponsor logged completion for 16 September 2025. Primary outcome, as filed: Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score. semaglutide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 1,840
- Started
- 2021-05-18
- Primary completion
- 2025-09-16 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score
Conditions studied
Early Alzheimer's Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.